151 related articles for article (PubMed ID: 36948666)
21. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker.
de Martino M; Klatte T; Haitel A; Marberger M
Cancer; 2012 Jan; 118(1):82-90. PubMed ID: 21713763
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects.
Kashyap MK; Kumar A; Emelianenko N; Kashyap A; Kaushik R; Huang R; Khullar M; Sharma SK; Singh SK; Bhargave AK; Upadhyaya SK
Biomarkers; 2005; 10(4):258-94. PubMed ID: 16191485
[TBL] [Abstract][Full Text] [Related]
24. [Renal cancer biomarkers. What is justified?].
Moch H
Pathologe; 2012 Nov; 33 Suppl 2():278-81. PubMed ID: 23052348
[TBL] [Abstract][Full Text] [Related]
25. Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities.
Yan BC; Mackinnon AC; Al-Ahmadie HA
Arch Pathol Lab Med; 2009 Jul; 133(7):1026-32. PubMed ID: 19642729
[TBL] [Abstract][Full Text] [Related]
26. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical diagnosis of renal neoplasms.
Truong LD; Shen SS
Arch Pathol Lab Med; 2011 Jan; 135(1):92-109. PubMed ID: 21204715
[TBL] [Abstract][Full Text] [Related]
28. Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.
Zhang L; Jiang H; Xu G; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y
Mol Med Rep; 2015 Jun; 11(6):4093-100. PubMed ID: 25673070
[TBL] [Abstract][Full Text] [Related]
29. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.
Lyskjær I; Iisager L; Axelsen CT; Nielsen TK; Dyrskjøt L; Fristrup N
Clin Cancer Res; 2024 Feb; 30(4):663-672. PubMed ID: 37874628
[TBL] [Abstract][Full Text] [Related]
30. Renal tumor natural history: the rationale and role for active surveillance.
Jewett MA; Zuniga A
Urol Clin North Am; 2008 Nov; 35(4):627-34; vii. PubMed ID: 18992616
[TBL] [Abstract][Full Text] [Related]
31. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
32. The genomics of renal cell carcinoma and its role in renal mass biopsy.
Salami SS; George AK; Udager AM
Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
[TBL] [Abstract][Full Text] [Related]
33. Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Iakymenko OA; Delma KS; Jorda M; Kryvenko ON
Int J Surg Pathol; 2021 Sep; 29(6):600-605. PubMed ID: 33764165
[No Abstract] [Full Text] [Related]
34. Urinary microRNAs: Looking for a New Tool in Diagnosis, Prognosis, and Monitoring of Renal Cancer.
Oto J; Plana E; Sánchez-González JV; García-Olaverri J; Fernández-Pardo Á; España F; Martínez-Sarmiento M; Vera-Donoso CD; Navarro S; Medina P
Curr Urol Rep; 2020 Mar; 21(2):11. PubMed ID: 32166474
[TBL] [Abstract][Full Text] [Related]
35. Selecting Patients with Small Renal Masses for Active Surveillance.
Johnson MH; Allaf ME; Pierorazio PM
Anticancer Agents Med Chem; 2018; 18(7):931-939. PubMed ID: 29141556
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma.
Hegele A; Heidenreich A; Kropf J; von Knobloch R; Varga Z; Hofmann R; Olbert P
Tumour Biol; 2004; 25(3):111-6. PubMed ID: 15361707
[TBL] [Abstract][Full Text] [Related]
37. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
38. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
39. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma.
Frantzi M; Metzger J; Banks RE; Husi H; Klein J; Dakna M; Mullen W; Cartledge JJ; Schanstra JP; Brand K; Kuczyk MA; Mischak H; Vlahou A; Theodorescu D; Merseburger AS
J Proteomics; 2014 Feb; 98():44-58. PubMed ID: 24374379
[TBL] [Abstract][Full Text] [Related]
40. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma.
Shalabi A; Abassi Z; Awad H; Halachmi S; Moskovitz B; Kluger Y; Nativ O
World J Urol; 2013 Dec; 31(6):1541-5. PubMed ID: 23430218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
